Evidence map›Paper›PMID 42094063›Full record

ArticleResearch square2026

Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway.

Yue Wang, Oliver Cope, Jingting Chen, Aarav Mehta, Dalia Fleifel, Christina G Ford, Poorya Behnamie, Molly Murray, Santiago Haase, Saygin Gulec and 12 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yue WangDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Oliver CopeIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Jingting ChenDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Aarav MehtaIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Dalia FleifelDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Christina G FordIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Poorya BehnamieIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Molly MurrayDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Santiago HaaseIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Saygin GulecComputational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Logan SladeDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Tim ElstonComputational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Philip M SpanheimerDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Caroline A TomblinBioskyrb Genomics, Inc. 2810 Meridian Pkwy Suite 110, Durham, NC 27713.
Alison M RojasBioskyrb Genomics, Inc. 2810 Meridian Pkwy Suite 110, Durham, NC 27713.
Tia TateBioskyrb Genomics, Inc. 2810 Meridian Pkwy Suite 110, Durham, NC 27713.
Jeremy E PurvisDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Jeremy WangDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Joseph M DahlBioskyrb Genomics, Inc. 2810 Meridian Pkwy Suite 110, Durham, NC 27713.
Samuel C WolffDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.
Jeanette Gowen CookDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.ORCID 0000-0003-0849-7405
Elizabeth BrunkDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516.ORCID 0000-0001-8578-8658

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Mathematical modeling of cellular signaling systemsR35GM127145 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Timothy C Elston · 2018 to 2026
$3.9M
Cell Cycle Dynamics that Ensure Genome MaintenanceR35GM141833 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN · 2021 to 2025
$2.8M
Cell cycle paths as a framework for understanding drug resistance in tumor cell subpopulationsR01CA280482 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeanette Gowen Cook, Michael James Emanuele · 2024 to 2026
$1.8M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA280482NIDDK NIH HHS P30 DK034987NIGMS NIH HHS R35 GM127145NIGMS NIH HHS R35 GM141833
6 · The paper itself

Abstract

During tumor progression, it has been assumed that individual cells that have acquired advantageous mutations overtake the population. Cancers driven by extrachromosomal DNA (ecDNA) do not follow this paradigm. Instead, these tumors have a spectrum of oncogene copy numbers across cells, and graded ecDNA variation may function as a form of bet-hedging that equips tumors with a broad range of phenotypes. Using imaging, single-cell multiomics, and multiplexed proteomics, we systematically characterized ecDNA levels across thousands of single cells. Higher ecDNA dosage produces proportional changes in transcript abundance, chromatin accessibility, protein levels, cell-cycle progression, and proliferation. Genes amplified on ecDNA exhibit distinct transcriptional scaling regimes that shift when the same genes are reintegrated into chromosomal homogeneous staining regions. When we experimentally disrupted the continuum of ecDNA dosage by sorting cells into low- and high-copy number states, the population rapidly recovered its original, continuous distribution. Our time-course data, live-cell imaging, and stochastic models collectively show that restoring this spectrum is an active, deterministic process rather than the passive outcome of random segregation. Together, these findings position ecDNA-mediated expression as a distinct evolutionary mechanism that endows tumors with rapid, population-level adaptability. These findings offer insight into why ecDNA-driven cancers are among the most aggressive and treatment-resistant.

Indexed as

ecDNAevolutionExtrachromosomal DNApopulation heterogeneitysingle cellsingle-cell multi-omics sequencing

Identifiers

PMID42094063
PMCPMC13142634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.